The government has contracted with a number of different companies (eg, recovery audit contractors, zone program integrity contractors, and Medicare contractors) to look at all Medicare payments and try to detect billing patterns that are outside the norm.
Urologists' reports of stones in pediatric patients varies by region.
Ever get paid by a pharmaceutical company for participating in research or making a speech? Has a drug rep ever bought you lunch or paid for a round of golf? Those practices could soon be a thing of the past.
To date, we have performed zero-ischemia RPN and LPN in more than 100 patients, including those with all types of challenging tumors. As a result of our growing experience, we now offer zero-ischemia RPN and LPN to virtually all comers, regardless of tumor location or renovascular anatomy.
Hypocitraturia is the leading metabolic risk factor in children with stone disease, and the majority of a study's cohort had an identifiable metabolic cause for their urolithiasis.
When legislative and regulatory initiatives pit one physician group against another, organizations such as the AMA or various state medical societies recognize they cannot win if they get involved in these battles.
An FDA advisory panel recommended against using the RANK ligand inhibitor denosumab (XGEVA) to delay or prevent the spread of castration-resistant prostate cancer in patients at high risk for bone metastases.
The Mount Sinai Hospital, New York, and Integrated Medical Professionals, PLLC (IMP)-a multispecialty practice that includes Advanced Urology Centers of New York and Advanced Radiation Centers of New York-have formed a partnership to provide easier access to screening, assessment, and treatment for complex urologic conditions, as well as improved access to radiation oncology services.
The National Quality Forum recently endorsed two outcomes-based measures from the American College of Surgeons that are pertinent to urology: surgical site infection and urinary tract infection.
Both the phosphodiesterase-type-5 inhibitor tadalafil (Cialis) and alpha-blocker tamsulosin (Flomax) appear to significantly improve scores on the International Prostate Symptom Score (IPSS) compared with placebo in men with signs and symptoms suggestive of BPH.
The FDA has approved Gen-Probe's Progensa PCA3 (Prostate Cancer gene 3) assay to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
Tracking PSA levels over time offers a more accurate assessment of the risk of life-threatening prostate cancer, and novel PSA velocity risk count testing associated with fluctuations in PSA levels may provide a more effective way to screen for clinically significant prostate cancer, a recent multicenter study concludes.
Give us your opinion on our latest poll, and see what your colleagues are saying. You can see the results of our previous surveys here as well.
Visit our Careers page for Urologists, which is updated regularly, to search for postings by date, location, and company name. You may also research salaries by using the PayScale tool link on the site.
Undiagnosed constipation, rather than problems with the bladder, may be to blame for nocturnal enuresis in some children, say researchers from Wake Forest Baptist Medical Center, Winston-Salem, NC.
Treatment with three relatively new targeted kidney cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute, Boston.
Short-term use of the cephalosporin antibiotic cefpodoxime proxetil (Vantin) for the treatment of women with uncomplicated cystitis did not meet criteria for noninferiority for achieving clinical cure compared with ciprofloxacin (Cipro, Proquin), say researchers from the University of Miami Miller School of Medicine.
Treatment with the investigational oral androgen receptor signaling inhibitor MDV3100 significantly improved overall survival in patients with advanced prostate cancer, recent phase III study results indicate.
A recent study has identified nearly 200 genes that may help explain how physical activity improves survival in men with low-grade prostate cancer.
A new American Association of Critical-Care Nurses (AACN) Practice Alert stresses the use of pre- and post-catheterization assessments to gauge proper catheter use and to monitor early signs of urinary tract infection.
Researchers have completed a systematic review of prognostic indices used to calculate a patient's life expectancy, and created a Web site that puts these indices in one central location.
Brachytherapy alone, or in combination with external beam radiation therapy (EBRT), significantly reduces mortality rates in patients with high-risk prostate cancer, report the authors of a study from Thomas Jefferson University, Philadelphia.
The FDA has approved the oral kinase inhibitor axitinib (Inlyta) for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.
The 5-alpha-reductase inhibitor dutasteride (Avodart) appears to delay disease progression and the initiation of active treatment in men with low-risk, localized prostate cancer, results of a 3-year international clinical trial indicate.
A new meshless cystocele repair procedure intended to circumvent the problems seen with traditional repair appears to be durable and cost effective.
Results from a retrospective review reveal that microsurgical subinguinal varicocelectomy increases serum testosterone levels in men with clinically palpable varicoceles.
Managing the urethral strictures and fistulas that sometimes follow prostate cancer therapies can be intimidating, but with experience, the presentations can be resolved with high success in a near majority of patients.
Urologists think it's up to parents to decide whether circumcision should be performed on their child.
In this era of ever-increasing pressure to meet quality standards, it behooves us as a specialty to not only read but to follow our evidence-based guidelines.